Return On Equity
44%
Third-party reference; reporting period not verified
Nurix Therapeutics, Inc. financial metrics
Period Q3 2026 · Filed 13 Oct 2026
Key metrics snapshot
Return On Assets
21%
Third-party reference; reporting period not verified
Operating Margin
83%
Third-party reference; reporting period not verified
Current Ratio
8.44x
Third-party reference; reporting period not verified
Quick Ratio
8.19x
Third-party reference; reporting period not verified
Debt-to-equity
0.07x
Third-party reference; reporting period not verified
Revenues YoY
739%
Trailing 12 months · Through 31 Aug 2026
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
44%
Third-party reference; reporting period not verified
|
|
| Return On Assets |
21%
Third-party reference; reporting period not verified
|
|
| Operating Margin |
83%
Third-party reference; reporting period not verified
|
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
8.44x
Third-party reference; reporting period not verified
|
|
| Quick Ratio |
8.19x
Third-party reference; reporting period not verified
|
|
| Debt-to-equity |
0.07x
Third-party reference; reporting period not verified
|
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| Revenues YoY |
739%
Trailing 12 months · 31 Aug 2026
|
|
| Net Income (Loss) Attributable to Parent |
$294,877,000
Trailing 12 months · 31 Aug 2026
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
109,249,814
Period-end balance · 30 Sep 2026
|
+42% |
| Common Stock, Shares, Outstanding |
109,200,394
Period-end balance · 31 Aug 2026
|
+42% |
| Common Stock, Value, Issued |
$109,000
Period-end balance · 31 Aug 2026
|
+42% |
| Weighted Average Number of Shares Outstanding, Basic |
111,563,067
Reported period · 31 Aug 2026
|
+33% |
| Weighted Average Number of Shares Outstanding, Diluted |
116,152,771
Reported period · 31 Aug 2026
|
+38% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$32,984,000
Period-end balance · 31 Aug 2026
|
+283% |
| Accounts Receivable, after Allowance for Credit Loss, Current |
$20,000,000
Period-end balance · 31 Aug 2026
|
|
| Accumulated Other Comprehensive Income (Loss), Net of Tax |
$210,000
Period-end balance · 31 Aug 2026
|
-276% |
| Assets |
$1,195,298,000
Period-end balance · 31 Aug 2026
|
+129% |
| Assets, Current |
$1,103,692,000
Period-end balance · 31 Aug 2026
|
+150% |
| Cash and Cash Equivalents, at Carrying Value |
$720,242,000
Period-end balance · 31 Aug 2026
|
+818% |
| Cash, Cash Equivalents, and Short-term Investments |
$1,100,000,000
Period-end balance · 31 Aug 2026
|
+157% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$721,024,000
Period-end balance · 31 Aug 2026
|
+808% |
| Common Stock, Par or Stated Value Per Share |
0.001
Period-end balance · 31 Aug 2026
|
0% |
| Common Stock, Shares Authorized |
500,000,000
Period-end balance · 31 Aug 2026
|
0% |
| Common Stock, Shares, Issued |
109,200,394
Period-end balance · 31 Aug 2026
|
+42% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent |
$294,548,000
Trailing 12 months · 31 Aug 2026
|
|
| Contract with Customer, Liability, Current |
$8,610,000
Period-end balance · 31 Aug 2026
|
-67% |
| Contract with Customer, Liability, Noncurrent |
$10,778,000
Period-end balance · 31 Aug 2026
|
-29% |
| Earnings Per Share, Basic |
2.5
Trailing 12 months · 31 Aug 2026
|
|
| Earnings Per Share, Diluted |
2.3
Trailing 12 months · 31 Aug 2026
|
|
| Employee-related Liabilities, Current |
$20,269,000
Period-end balance · 31 Aug 2026
|
+24% |
| General and Administrative Expense |
$78,205,000
Trailing 12 months · 31 Aug 2026
|
+57% |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest |
$563,413,000
Reported period · 31 Aug 2026
|
|
| Income Tax Expense (Benefit) |
$13,064,000
Trailing 12 months · 31 Aug 2026
|
+1601% |
| Liabilities |
$226,987,000
Period-end balance · 31 Aug 2026
|
+51% |
| Liabilities and Equity |
$1,195,298,000
Period-end balance · 31 Aug 2026
|
+129% |
| Liabilities, Current |
$130,742,000
Period-end balance · 31 Aug 2026
|
+59% |
| Operating Income (Loss) |
$289,657,000
Trailing 12 months · 31 Aug 2026
|
|
| Operating Lease, Liability, Current |
$3,241,000
Period-end balance · 31 Aug 2026
|
-15% |
| Operating Lease, Liability, Noncurrent |
$62,091,000
Period-end balance · 31 Aug 2026
|
+18% |
| Operating Lease, Right-of-Use Asset |
$48,631,000
Period-end balance · 31 Aug 2026
|
-8.3% |
| Other Assets, Noncurrent |
$7,954,000
Period-end balance · 31 Aug 2026
|
+7.9% |
| Preferred Stock, Par or Stated Value Per Share |
0.001
Period-end balance · 31 Aug 2026
|
0% |
| Preferred Stock, Shares Authorized |
10,000,000
Period-end balance · 31 Aug 2026
|
0% |
| Preferred Stock, Shares Issued |
0
Period-end balance · 31 Aug 2026
|
|
| Preferred Stock, Shares Outstanding |
0
Period-end balance · 31 Aug 2026
|
|
| Property, Plant and Equipment, Gross |
$62,875,000
Period-end balance · 31 Aug 2026
|
+2.7% |
| Property, Plant and Equipment, Net |
$19,407,000
Period-end balance · 31 Aug 2026
|
-5.3% |
| Research and Development Expense |
$334,074,000
Trailing 12 months · 31 Aug 2026
|
+11% |
| Retained Earnings (Accumulated Deficit) |
$630,128,000
Period-end balance · 31 Aug 2026
|
+32% |
| Revenue from Contract with Customer, Excluding Assessed Tax |
$701,936,000
Trailing 12 months · 31 Aug 2026
|
+739% |
| Stockholders' Equity Attributable to Parent |
$968,311,000
Period-end balance · 31 Aug 2026
|
+160% |
Comparisons, sources and research notes
Sources and sharing
NRIX - Nurix Therapeutics, Inc. Financial Facts
- Context
- Latest metrics period: Q3 2026
- Latest reported value
- Return On Equity 44%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2026
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2026.
- Most recent SEC facts end date on this page: 30 Sep 2026.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for NRIX - Nurix Therapeutics, Inc.
Latest financial period: Q3 2026. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
13 Oct 2026
Page type
Company facts
Latest period
Q3 2026
SEC-backed company facts were refreshed from filings filed on 13 Oct 2026.
Benchmark Context
How Return On Equity compares
Return On Equity does not yet have enough prior-period data for a historical comparison on this page.
Compared with
Compared with Nurix Therapeutics, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2026.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Revenue on this page
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Filing notes and source
Key facts
- NRIX - Nurix Therapeutics, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q3 2026.
- Headline metric: Return On Equity 44%.
Change
- Comparable YoY change is unavailable for this metric.
- Most recent SEC facts end date: 30 Sep 2026.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2026-09-30) highlights Return On Equity 44.0%, Return On Assets 21.1%, and Operating Margin 83.1%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
DCF value materially below price
Overvalued
Low confidence
-204%
fair value gap
Fair value per share
$24.62
Market price
$23.71
NRIX - Local security
PEG ratio
2.3x
P/E 9.3x / growth 4%
DCF Growth Assumption
Enterprise value
$3.96B
Equity value
$2.86B
DCF fair value scenarios
Bear
$15.97
- Growth
- 1%
- Discount
- 11%
- Terminal
- 2%
Gap -167%
Base
$24.62
- Growth
- 4%
- Discount
- 10%
- Terminal
- 2.5%
Gap -204%
Bull
$38.23
- Growth
- 7%
- Discount
- 9%
- Terminal
- 3%
Gap -261%
Base growth: DCF Growth Assumption.
Key valuation metrics
EV/Revenue
2.4x
Local security market EV / SEC revenue
EV/EBITDA
n/a
Local security market EV / SEC EBITDA
Ebitda is unavailable or not positive
P/E
9.3x
Local security market price / SEC EPS
P/S
3.9x
Local security market cap / SEC revenue
P/B
2.8x
Local security market cap / SEC equity
PEG
2.3x
P/E / DCF Growth Assumption
Core assumptions
- Projection
- 5 years
- FCF growth
- 4%
- Discount rate
- 10%
- Terminal growth
- 2.5%
SEC fact inputs
- DCF base FCF
- $271.85M
- Trailing SEC FCF
- Reported FCF
- $271.85M
- Net income
- $294.88M
- EBITDA
- n/a
- Cash
- $1.1B
- Debt
- n/a
- Equity
- $968.31M
- Shares
- 116,152,771
Data confidence notes
- Dcf base free cash flow: dcf base starts from trailing sec free cash flow
- Dcf base free cash flow: trailing free cash flow is not positive
- Dcf confidence is low for this sec-only free cash flow estimate
- Debt missing: equity value treats debt as 0
- Base free cash flow is negative; dcf output is mechanically computed but high risk
Compare This Company Through SEC-backed Metrics
Use these links to compare NRIX - Nurix Therapeutics, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
Revenues YoY
Latest value: 739%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
77.6/100
Balanced Confidence medium
Return On Equity
44%
Metric score 100.0/100
Return On Assets
21%
Metric score 100.0/100
Financial Health
- Current Ratio
- 8.44x
- Quick Ratio
- 8.19x
- Debt to Equity
- 0.07x
Strengths
Return On Equity, Return On Assets, and Operating Margin
Watchpoints
Current Ratio and Quick Ratio
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first